(UroToday.com) Following androgen deprivation therapy (ADT) which was introduced decades prior, the TAX-327 trial of docetaxel for patients with metastatic castration-resistant prostate cancer was the first to demonstrate a survival advantage for systemic treatment in prostate cancer. Since then, docetaxel has proven survival benefit for men with metastatic castration-sensitive disease. However, docetaxel requires the non-ionic surfactant polysorbate 80 which is associated with hypersensitivity to allow for IV solubility, necessitating steroid pre-medication. While oral treatment may improve tolerability and improve convenience, docetaxel has poor oral bioavailability due to extrusion by intestinal p-glycoprotein. In the Prostate, Testicular, Penile Poster session at the 2021 American Society of Clinical Oncology Annual Meeting, Dr. Christopher Jackson presented an assessment of Oradoxel, a new combination of oral docetaxel capsules plus the novel gut-selective P-glycoprotein inhibitor encequidar (HM30181A). This agent has already been used in combination with oral paclitaxel.